Multimodal imaging based on MRI and PET reveals [ 18 F]FLT PET as a specific and early indicator of treatment efficacy in a preclinical model of recurrent glioblastoma

摘要: The primary objective of this study was to compare the ability PET and MRI biomarkers predict treatment efficacy in a preclinical model recurrent glioblastoma multiforme. (anatomical, diffusion, vasculature oxygenation) ([18F]FDG [18F]FLT) parameters were obtained 3 days after end compared with late tumour growth survival. Early recurrence, no effect temozolomide combined bevacizumab observed on volume as assessed by T2-W MRI. At later times, decreased increased Interestingly, at earlier time, temozolomide + bevacizumab [18F]FLT uptake, cerebral blood oedema. oedema correlated overall survival but uptake had highest specificity sensitivity for early prediction efficacy. present investigation recurrence underscores importance multimodal imaging assessment oedema, vascular status cell proliferation. Finally, holds greatest promise These findings may translate clinically that individualized glioma could be prescribed patients selected PET/MRI examinations.